S. Verelst

598 total citations
14 papers, 337 citations indexed

About

S. Verelst is a scholar working on Hematology, Oncology and Molecular Biology. According to data from OpenAlex, S. Verelst has authored 14 papers receiving a total of 337 indexed citations (citations by other indexed papers that have themselves been cited), including 12 papers in Hematology, 7 papers in Oncology and 6 papers in Molecular Biology. Recurrent topics in S. Verelst's work include Multiple Myeloma Research and Treatments (11 papers), Cancer Treatment and Pharmacology (5 papers) and Protein Degradation and Inhibitors (4 papers). S. Verelst is often cited by papers focused on Multiple Myeloma Research and Treatments (11 papers), Cancer Treatment and Pharmacology (5 papers) and Protein Degradation and Inhibitors (4 papers). S. Verelst collaborates with scholars based in Netherlands, Switzerland and United Kingdom. S. Verelst's co-authors include Pieter Sonneveld, Hedwig M. Blommestein, Peter C. Huijgens, Simone Oerlemans, Allert H. Vos, Floortje Mols, Ad Koster, Lonneke V. van de Poll‐Franse, Carin A. Uyl‐de Groot and Vanessa C. Gray‐Schopfer and has published in prestigious journals such as Blood, Leukemia and Value in Health.

In The Last Decade

S. Verelst

12 papers receiving 324 citations

Peers — A (Enhanced Table)

Peers by citation overlap · career bar shows stage (early→late) cites · hero ref

Name h Career Trend Papers Cites
S. Verelst Netherlands 6 261 218 139 46 36 14 337
Richy Agajanian United States 10 150 0.6× 145 0.7× 130 0.9× 29 0.6× 47 1.3× 32 318
Alain Flinois Switzerland 9 365 1.4× 254 1.2× 269 1.9× 54 1.2× 24 0.7× 25 467
Ulf Christian Frølund Denmark 10 247 0.9× 156 0.7× 163 1.2× 75 1.6× 21 0.6× 27 318
Jagoda Jasielec United States 13 390 1.5× 252 1.2× 339 2.4× 44 1.0× 41 1.1× 40 553
Maxim Norkin United States 12 231 0.9× 148 0.7× 86 0.6× 52 1.1× 41 1.1× 35 396
Xenofon Papanikolaou United States 7 241 0.9× 150 0.7× 167 1.2× 50 1.1× 21 0.6× 30 310
Campbell Tiley Australia 10 216 0.8× 159 0.7× 78 0.6× 32 0.7× 40 1.1× 25 351
Janice Reed United States 10 307 1.2× 220 1.0× 271 1.9× 71 1.5× 27 0.8× 25 426
Esprit Ma United States 9 159 0.6× 102 0.5× 82 0.6× 32 0.7× 58 1.6× 44 274
Dorte Tholstrup Denmark 6 88 0.3× 180 0.8× 87 0.6× 26 0.6× 55 1.5× 10 303

Countries citing papers authored by S. Verelst

Since Specialization
Citations

This map shows the geographic impact of S. Verelst's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by S. Verelst with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites S. Verelst more than expected).

Fields of papers citing papers by S. Verelst

Since Specialization
Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by S. Verelst. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by S. Verelst. The network helps show where S. Verelst may publish in the future.

Co-authorship network of co-authors of S. Verelst

This figure shows the co-authorship network connecting the top 25 collaborators of S. Verelst. A scholar is included among the top collaborators of S. Verelst based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with S. Verelst. S. Verelst is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

14 of 14 papers shown
1.
Dierick, Jean‐François, et al.. (2020). A deadly capillary leak attack. Clarkson’s disease: a narrative review. Acta Clinica Belgica. 77(1). 219–226. 2 indexed citations
2.
Verelst, S., Hedwig M. Blommestein, Saskia de Groot, et al.. (2018). Long‐term Outcomes in Patients With Multiple Myeloma. HemaSphere. 2(4). e45–e45. 41 indexed citations
3.
Blommestein, Hedwig M., S. Verelst, Saskia de Groot, et al.. (2015). A cost‐effectiveness analysis of real‐world treatment for elderly patients with multiple myeloma using a full disease model. European Journal Of Haematology. 96(2). 198–208. 28 indexed citations
4.
Verelst, S., Yvette van Norden, & Pieter Sonneveld. (2015). Age versus frailty: What should determine treatment choice in the elderly myeloma patients these days?. Clinical Lymphoma Myeloma & Leukemia. 15. e69–e70. 1 indexed citations
5.
Blommestein, Hedwig M., M Franken, S. Verelst, et al.. (2014). Access to expensive cancer drugs in Dutch daily practice: should we be concerned?. PubMed. 72(4). 235–41. 4 indexed citations
6.
Blommestein, Hedwig M., et al.. (2013). One Line Does Not Make a Picture: Real-World Cost-Effectiveness of Multiple Myeloma Treatments Using a Full Disease Model. Value in Health. 16(7). A408–A408. 1 indexed citations
7.
Blommestein, Hedwig M., S. Verelst, Saskia de Groot, et al.. (2013). One Line Does Not Make a Picture: Real-World Cost-Effectiveness Of Multiple Myeloma Treatments Using a Full Disease Model. Blood. 122(21). 2930–2930. 1 indexed citations
8.
Sonneveld, Pieter, S. Verelst, Philip Lewis, et al.. (2013). Review of health-related quality of life data in multiple myeloma patients treated with novel agents. Leukemia. 27(10). 1959–1969. 76 indexed citations
9.
Blommestein, Hedwig M., S. Verelst, Peter C. Huijgens, et al.. (2012). Real-world costs of autologous and allogeneic stem cell transplantations for haematological diseases: a multicentre study. Annals of Hematology. 91(12). 1945–1952. 46 indexed citations
10.
11.
Mols, Floortje, Simone Oerlemans, Allert H. Vos, et al.. (2012). Health‐related quality of life and disease‐specific complaints among multiple myeloma patients up to 10 yr after diagnosis: results from a population‐based study using the PROFILES registry. European Journal Of Haematology. 89(4). 311–319. 100 indexed citations
12.
Verelst, S., Fabian Termorshuizen, Carin A. Uyl‐de Groot, et al.. (2011). Effect of thalidomide with melphalan and prednisone on health-related quality of life (HRQoL) in elderly patients with newly diagnosed multiple myeloma: a prospective analysis in a randomized trial. Annals of Hematology. 90(12). 1427–1439. 29 indexed citations
13.
Verelst, S., Hedwig M. Blommestein, Henrike E. Karim‐Kos, Peter C. Huijgens, & Pieter Sonneveld. (2011). Trends in Incidence and Survival of Multiple Myeloma in the Netherlands in the Last Two Decades. Results From a National Population Based Study. Blood. 118(21). 5071–5071. 3 indexed citations
14.

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact

Breakdown of academic impact, for papers by Richy Agajanian Breakdown of academic impact, for papers by Alain Flinois Breakdown of academic impact, for papers by Ulf Christian Frølund Breakdown of academic impact, for papers by Jagoda Jasielec Breakdown of academic impact, for papers by Maxim Norkin Breakdown of academic impact, for papers by Xenofon Papanikolaou Breakdown of academic impact, for papers by Campbell Tiley Breakdown of academic impact, for papers by Janice Reed Breakdown of academic impact, for papers by Esprit Ma Breakdown of academic impact, for papers by Dorte Tholstrup
Rankless by CCL
2026